[go: up one dir, main page]

CA2521809A1 - Vaccins ameliores a base de proteines de choc thermique et immunotherapies associees - Google Patents

Vaccins ameliores a base de proteines de choc thermique et immunotherapies associees Download PDF

Info

Publication number
CA2521809A1
CA2521809A1 CA002521809A CA2521809A CA2521809A1 CA 2521809 A1 CA2521809 A1 CA 2521809A1 CA 002521809 A CA002521809 A CA 002521809A CA 2521809 A CA2521809 A CA 2521809A CA 2521809 A1 CA2521809 A1 CA 2521809A1
Authority
CA
Canada
Prior art keywords
seq
leu
trp
arg
phe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002521809A
Other languages
English (en)
Inventor
Jessica Baker Flechtner
Kenya Prince-Cohane
Sunil Mehta
Paul Slusarewicz
Sofija Andjelic
Brian H. Barber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agenus Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/776,521 external-priority patent/US7420037B2/en
Priority claimed from US10/820,067 external-priority patent/US7309491B2/en
Application filed by Individual filed Critical Individual
Publication of CA2521809A1 publication Critical patent/CA2521809A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des antigènes hybrides comportant au moins un domaine antigénique, au moins un domaine de liaison à des protéines de choc thermique, et au moins un lieur peptidique amélioré entre les deux domaines, lesdits antigènes s'avérant utiles pour l'induction d'une réponse immunitaire vis-à-vis du domaine antigénique lorsqu'ils sont administrés seuls ou dans un complexe avec au moins une protéine de choc thermique. Ces antigènes hybrides et les complexes associés peuvent être utilisés pour traiter des maladies infectieuses et des cancers qui expriment un antigène du domaine antigénique.
CA002521809A 2003-04-11 2004-04-09 Vaccins ameliores a base de proteines de choc thermique et immunotherapies associees Abandoned CA2521809A1 (fr)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US46246903P 2003-04-11 2003-04-11
US60/462,469 2003-04-11
US46374603P 2003-04-18 2003-04-18
US60/463,746 2003-04-18
US50341703P 2003-09-16 2003-09-16
US60/503,417 2003-09-16
US10/776,521 2004-02-12
US10/776,521 US7420037B2 (en) 2003-02-13 2004-02-12 Heat shock protein-based vaccines and immunotherapies
PCT/US2004/004340 WO2004071457A2 (fr) 2003-02-13 2004-02-13 Vaccins et immunotherapies ameliores a base de proteine de choc thermique
USPCT/US04/04340 2004-02-13
US10/820,067 US7309491B2 (en) 2003-04-11 2004-04-08 Heat shock protein-based vaccines and immunotherapies
US10/820,067 2004-04-08
PCT/US2004/010983 WO2004091493A2 (fr) 2003-04-11 2004-04-09 Vaccins ameliores a base de proteines de choc thermique et immunotherapies associees

Publications (1)

Publication Number Publication Date
CA2521809A1 true CA2521809A1 (fr) 2004-10-28

Family

ID=35539709

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002521809A Abandoned CA2521809A1 (fr) 2003-04-11 2004-04-09 Vaccins ameliores a base de proteines de choc thermique et immunotherapies associees

Country Status (8)

Country Link
EP (1) EP1617804A4 (fr)
JP (1) JP2007525448A (fr)
KR (1) KR20050121721A (fr)
AU (1) AU2004229458B2 (fr)
BR (1) BRPI0409321A (fr)
CA (1) CA2521809A1 (fr)
MX (1) MXPA05010881A (fr)
WO (1) WO2004091493A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8541002B2 (en) * 2003-09-12 2013-09-24 Agenus Inc. Vaccine for treatment and prevention of herpes simplex virus infection
EP1874343A4 (fr) 2005-04-19 2009-07-22 Lilly Co Eli Anatigènes polysaccharidiens synthétiques monovalents et polyvalents pour intervention immunologique en pathologie
CY1112212T1 (el) * 2008-04-24 2015-12-09 Immatics Biotechnologies Gmbh Νεα σκευασματα πεπτιδιων που σχετιζονται με ογκους τα οποια συνδεονται σε μορια του αντιγονου ανθρωπινων λευκοκυτταρων (hla) ταξης i ή ii για εμβολια
PL2113253T3 (pl) * 2008-04-30 2010-09-30 Immatics Biotechnologies Gmbh Nowa postać leku - preparat zawierający peptydy nowotworowe wiążące się z antygenami ludzkich leukocytów klasy I i II, zastosowany w szczepionce
US20140255449A1 (en) * 2011-07-21 2014-09-11 Biotech Tools S.A. Dosage of dnak
EP3294324A1 (fr) * 2015-05-13 2018-03-21 Agenus Inc. Vaccins pour le traitement et la prévention du cancer
WO2019210055A2 (fr) 2018-04-26 2019-10-31 Agenus Inc. Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9202219D0 (en) * 1992-02-03 1992-03-18 Connaught Lab A synthetic heamophilus influenzae conjugate vaccine
AU712907B2 (en) * 1995-08-18 1999-11-18 Sloan-Kettering Institute For Cancer Research Method for treatment of cancer and infectious diseases and compositions useful in same
CA2308299A1 (fr) * 1997-10-31 1999-05-14 Sloan-Kettering Institute For Cancer Research Peptides conjugues se liant aux proteines du stress
WO2001078655A2 (fr) * 2000-04-17 2001-10-25 Alan Houghton Procedes et compositions pour l'immunotherapie du melanome induite par proteine de stress
US20040071656A1 (en) * 2001-12-26 2004-04-15 Felix Wieland Modulation of heat-shock-protein-based immunotherapies
US7420037B2 (en) * 2003-02-13 2008-09-02 Antigenics Inc. Heat shock protein-based vaccines and immunotherapies

Also Published As

Publication number Publication date
EP1617804A4 (fr) 2007-07-25
KR20050121721A (ko) 2005-12-27
WO2004091493A3 (fr) 2006-04-20
AU2004229458B2 (en) 2009-11-19
EP1617804A2 (fr) 2006-01-25
AU2004229458A1 (en) 2004-10-28
MXPA05010881A (es) 2006-05-31
BRPI0409321A (pt) 2006-05-23
WO2004091493A2 (fr) 2004-10-28
JP2007525448A (ja) 2007-09-06

Similar Documents

Publication Publication Date Title
US6663868B1 (en) Heat shock protein-based vaccines and immunotherapies
US7420037B2 (en) Heat shock protein-based vaccines and immunotherapies
Ma et al. Heat shock protein 70/MAGE-3 fusion protein vaccine can enhance cellular and humoral immune responses to MAGE-3 in vivo
US6719974B1 (en) Heat shock protein-based vaccines and immunotherapies
US7618637B2 (en) Heat shock protein-based vaccines and immunotherapies
JP2003519668A (ja) 熱ショックタンパク質融合タンパク質による、ｃｄ４＋ｔ細胞非依存性のインビボｃｔｌ惹起による個別ａｔｐ結合ドメインのマッピング
US7309491B2 (en) Heat shock protein-based vaccines and immunotherapies
AU2004229458B2 (en) Improved heat shock protein-based vaccines and immunotherapies
US6773707B1 (en) Heat shock protein-based vaccines and immunotherapies
Vatner et al. The tailless complex polypeptide-1 ring complex of the heat shock protein 60 family facilitates cross-priming of CD8 responses specific for chaperoned peptides
Vatner et al. The Tailless Complex Polypeptide-1 Ring

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20100409